#United States #New Orleans #InsightRX #ASHP #Pharmacokinetics

InsightRX at ASHP 2024 Midyear Clinical Meeting

SAN FRANCISCO, Dec. 3, 2024 - InsightRX, renowned for its expertise in Bayesian model-informed precision dosing (MIPD) software, is set to make waves at the upcoming ASHP 2024 Midyear Clinical Meeting. Scheduled from December 8-12 at the Ernest N. Morial Convention Center in New Orleans, this event, organized by the American Society of Health-System Pharmacists, will gather pharmacy professionals for a comprehensive exchange of knowledge.

Engagements and Presentations

Notably, InsightRX will not only exhibit at booth 1340 but will also feature a presentation from Senior Director of Product and Customer Experience, Jonathan Faldasz, PharmD, BCPS. On December 9, from 2:00 to 3:30 PM, he will present research pertaining to the Cockcroft-Gault equation, traditionally used to estimate renal function. This research, derived from a massive dataset of nearly 100,000 patients with low serum creatinine levels, highlights inaccuracies in the equation’s predictions for this specific demographic. A newly proposed equation that takes adjusted serum creatinine into account will be discussed, showing promising improvements in predictive accuracy.

Groundbreaking Feature: InsightRX Gemini

A major highlight at this year’s ASHP meeting will be the demonstration of InsightRX Gemini, a cutting-edge enhancement to the Nova platform. This feature simplifies the pharmacokinetic (PK) model selection process by automatically selecting the optimal model based on crucial patient data, analyzed from approximately 400,000 vancomycin treatment courses. InsightRX has demonstrated that using Gemini can significantly increase dosing accuracy for individual patients by up to 47.2%, improve precision by 25%, and minimize bias by 93%. These advancements signify a significant leap towards more personalized medicine.

Expanding Precision Dosing Applications

Beyond vancomycin, InsightRX has curated a rich array of Drug Modules that will be showcased throughout the meeting. Key highlights include:

• - Antifungals: Research validates a model-informed precision dosing strategy for posaconazole, vital in treating invasive fungal diseases. Enhancing treatment personalization could be a game-changer.
• - Beta-lactams: InsightRX sheds light on the critical need for therapeutic drug monitoring (TDM), which holds potential in refining antibiotic dosing in vulnerable patient populations.
• - Solid Organ Transplant: Current practices for monitoring tacrolimus may not correlate well with outcomes. Insights into Bayesian estimation methods may reshape future monitoring practices.
• - Bone Marrow Transplant: Personalized dosing strategies for busulfan show promise, with InsightRX's simulations indicating higher target attainment through improved estimation approaches.
• - Anticoagulants: Developing MIPD applications for heparin individualizes therapy and aims to reduce complications associated with coagulation-related risks.
• - Inflammatory Bowel Disease: Adjusting infliximab dosing based on serum concentrations has shown potential in maximizing efficacy for pediatric patients.

A Vision for the Future

InsightRX’s CEO, Sirj Goswami, PhD, reflects on the year, noting the company's significant growth and accomplishments. He expresses excitement for the upcoming discussions at ASHP, emphasizing the potential of model-informed precision dosing to enhance clinical outcomes and operational efficacy.

As a leader in healthcare technology, InsightRX continues to innovate with a cloud-based clinical decision support platform. By applying advanced quantitative pharmacology and artificial intelligence, they aim to improve therapeutic decision-making from drug development to clinical practice.

For attendees at ASHP 2024, InsightRX promises to deliver invaluable insights and transformative technologies for improved patient care.